Magaldrato Special Product’s Line

Magaldrate, the active ingredient in Magaldrato Special Product’s Line, is an antacid presented as an oral formulation for oral use. It neutralizes excess stomach acid and is used to relieve symptoms of heartburn, dyspepsia and other acidity‑related gastrointestinal discomforts.

GNH USA supplies Magaldrato Special Product’s Line as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable supply chains and responsive technical support throughout the procurement process.

Magaldrate is an antacid that acts on gastric acidity to provide symptomatic relief in several common gastrointestinal conditions.

- Heartburn: reduces burning sensation by neutralizing stomach acid. - Dyspepsia: alleviates upper abdominal discomfort and fullness. - Gastric acidity: lowers overall gastric acidity, helping prevent acid‑related mucosal irritation.

Magaldrate may cause adverse reactions, most of which are mild and related to its mineral content.

Common Side Effects: - Constipation: aluminum component may slow intestinal transit. - Diarrhea: magnesium can increase bowel movements. - Nausea: mild stomach upset after ingestion. - Metallic taste: transient taste alteration. - Flatulence: gas production from acid neutralization. - Abdominal cramps: mild cramping in the upper abdomen. - Dry mouth: reduced salivation in some individuals.

Serious or Rare Side Effects: - Hypermagnesemia: elevated magnesium levels, especially in renal impairment. - Aluminum toxicity: neurological symptoms with prolonged high‑dose use. - Severe electrolyte imbalance: abnormal calcium or phosphate levels that may affect cardiac function. - Anaphylactic reaction: rare hypersensitivity requiring immediate medical attention.

When using Magaldrate, certain precautions should be observed to ensure safety and effectiveness.

- Renal function assessment: evaluate kidney function before initiating therapy, especially in patients with known renal disease. - Dose adjustment in renal impairment: reduce dose or avoid use in severe renal failure to prevent accumulation of magnesium or aluminum. - Monitor electrolytes: periodic checking of serum magnesium, calcium and phosphate levels during prolonged treatment. - Avoid concurrent use with drugs requiring acidic pH: antacids may reduce absorption of tetracyclines, quinolones, iron salts and certain antivirals. - Use with adequate hydration: maintain sufficient fluid intake to minimize constipation risk. - Store at room temperature: keep in the original container, protect from moisture and heat.

Magaldrate can affect the absorption or efficacy of several medications; interactions are classified by their clinical significance.

Major Interactions (Avoid): - Tetracycline antibiotics: antacid reduces absorption, decreasing effectiveness. - Fluoroquinolone antibiotics: chelation may lower drug levels. - Iron supplements: concurrent use impairs iron absorption. - Digoxin: altered absorption may affect therapeutic levels. - Atazanavir (and other protease inhibitors): reduced bioavailability.

Moderate Interactions (Monitor Closely): - Warfarin: antacid may alter INR, requiring monitoring. - Levothyroxine: reduced absorption, dose adjustment may be needed. - Beta‑blockers: possible change in plasma concentration. - Calcium channel blockers: monitor for altered effect.